Group B for Corneal Edema After Cataract Surgery

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Durrie Vision, Overland Park, KS
Corneal Edema After Cataract Surgery+3 More
Ripasudil - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to assess the safety and efficacy of K-321 in subjects after cataract surgery

Eligible Conditions

  • Corneal Edema After Cataract Surgery

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Corneal Edema After Cataract Surgery

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Baseline to Week 26

Baseline to Week 26
Change from baseline in Best-Corrected Visual Acuity (BCVA)
Change from baseline in Central Corneal Endothelial Cell Density (ECD)
Change from baseline in Corneal Thickness
Change from baseline in Peripheral Corneal ECD
Change in Vision-related quality of life
Safety Assessment
Week 26
Change from baseline in corneal edema

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Corneal Edema After Cataract Surgery

Trial Design

4 Treatment Groups

Group B
1 of 4
Group A
1 of 4
Group C
1 of 4
Group D
1 of 4
Experimental Treatment
Non-Treatment Group

330 Total Participants · 4 Treatment Groups

Primary Treatment: Group B · Has Placebo Group · Phase 3

Group B
Drug
Experimental Group · 1 Intervention: Ripasudil · Intervention Types: Drug
Group A
Drug
Experimental Group · 1 Intervention: Ripasudil · Intervention Types: Drug
Group C
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Group D
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to week 26
Closest Location: Durrie Vision · Overland Park, KS
2011First Recorded Clinical Trial
1 TrialsResearching Corneal Edema After Cataract Surgery
15 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years old.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.